MAM
HZNP

Meeder Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Meeder Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-162
Closed -$10K – 2205
2022
Q3 		$10K Sell
162
-75
-32% -$5.24K ﹤0.01% 1340
2022
Q2 		$19K Sell
237
-206
-47% -$19.5K ﹤0.01% 1163
2022
Q1 		$47K Sell
443
-20,208
-98% -$1.97M ﹤0.01% 991
2021
Q4 		$2.23M Sell
20,651
-2,659
-11% -$290K 0.22% 77
2021
Q3 		$2.55M Buy
23,310
+1,060
+5% +$110K 0.13% 137
2021
Q2 		$2.08M Buy
22,250
+36
+0.2% +$3.31K 0.1% 167
2021
Q1 		$2.04M Buy
22,214
+22,103
+19,913% +$1.87M 0.1% 166
2020
Q4 		$8K Sell
111
-24,149
-100% -$1.8M ﹤0.01% 1083
2020
Q3 		$1.88M Buy
24,260
+15,214
+168% +$1.05M 0.12% 142
2020
Q2 		$503K Buy
9,046
+30
+0.3% +$1.28K 0.03% 361
2020
Q1 		$266K Buy
9,016
+1,860
+26% +$62.9K 0.02% 496
2019
Q4 		$259K Sell
7,156
-2,054
-22% -$63K 0.02% 538
2019
Q3 		$250K Sell
9,210
-13,782
-60% -$356K 0.02% 553
2019
Q2 		$553K Buy
22,992
+5,649
+33% +$143K 0.04% 395
2019
Q1 		$458K Buy
17,343
+7,396
+74% +$175K 0.04% 388
2018
Q4 		$194K Buy
9,947
+8,588
+632% +$168K 0.02% 504
2018
Q3 		$27K Buy
1,359
+914
+205% +$17.4K ﹤0.01% 955
2018
Q2 		$7.37K Sell
445
-196
-31% -$2.99K ﹤0.01% 1180
2018
Q1 		$9K Buy
641
+141
+28% +$2.08K ﹤0.01% 1110
2017
Q4 		$7K Buy
500
+320
+178% +$4.49K ﹤0.01% 1245
2017
Q3 		$2K Sell
180
-1,093
-86% -$13.9K ﹤0.01% 1513
2017
Q2 		$15K Buy
1,273
+820
+181% +$10.2K ﹤0.01% 896
2017
Q1 		$7K Buy
+453
New +$7.34K ﹤0.01% 982

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Meeder Asset Management's HZNP Position: Q4 2022 in Review

Meeder Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 162 shares — an estimated $10K sold.

Meeder Asset Management first reported a position in HZNP in Q1 2017 and held it in 23 quarters. The position peaked at $2.55M in Q3 2021. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Meeder Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 162 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $10K.
  • Meeder Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2017 and held it in 23 quarters.
  • Meeder Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.55M in Q3 2021.
  • 613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.